Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026

Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026

Press Release Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026February 10, 2026 - release at 7:30 am Sophia Antipolis,...

Nicox to Present Phase 3 NCX 470 Data at 2026 American Glaucoma Society Annual Meeting

Nicox SA announced that results from its phase 3 clinical development program for NCX 470 will be presented at the upcoming American Glaucoma Society (AGS) annual meeting, taking place February 19–22, 2026, in Rancho Mirage, California. The presentations will include two podium presentations and one poster session highlighting efficacy, safety, and mechanistic data from advanced clinical studies. NCX 470 is a novel nitric oxide-donating bimatopr…